 Home > Medical News > Medical Research Articles > Bojian AD treatment drug gosuranemab phase 2 clinical failure

Bojian AD treatment drug gosuranemab phase 2 clinical failure

 Last Update: 2021-06-30
 Source: Internet
 Author: User

Tags

vitamin b6 daily dose

methotrexate injection dose

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

According to foreign media reports, Bojian announced the results of the Phase 2 TANGO study of Gosuranemab (BIIB092) on June 16
.

Gosuranemab is an experimental anti-tau antibody that is currently being evaluated as a potential drug for the treatment of Alzheimer's disease

In patients with mild cognitive impairment (MCI) due to Alzheimer’s disease and mild Alzheimer’s disease, compared with placebo, Gosuranemab’s clinical dementia rating scale-box sum (CDR) at week 78 -SB) did not reach its primary efficacy endpoint for dementia
.

In exploratory efficacy endpoints, including Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog 13), Alzheimer's Disease Cooperative Research Activity of Daily Life (ADCS-ADL), Mini Mental State Examination (MMSE) No treatment benefit and function assessment questionnaire (FAQ) was found

The Phase 2 TANGO study of Gosuranemab is a 78-week double-blind, placebo-controlled, parallel-group trial to evaluate the safety of patients with MCI or mild AD caused by Alzheimer's disease (AD) in slowing clinical progression Sex and effectiveness, followed by a long-term extension of dose-blindness
.

The study recruited 654 participants in 97 locations
.

Participants aged 50-80 with gradual and progressive changes in memory function for more than 6 months meet all clinical criteria for MCI caused by AD or mild AD.

Gosuranemab is an antibody against the N-terminus of tau protein
.

Consistent with previous studies, the target participation was demonstrated by reducing the N-terminal tau in CSF

Based on these results, the TANGO study has been terminated
.

Biogen will stop the clinical development of Gosuranemab

Reference source: Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer's Disease

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Semiglutide 99% Hot Sale Pharmaceutical Best Service Pharmaceutical Producer

CAS No.:

pharm grade

$140.00/G FOB

Carboxylated Styrene-Butadiene latex (XSBR)

CAS No.: 25085-39-6

Different Grade

$0.1/KG EXW

High quality Pure 99% 4,16-Androstadien-3-one Androstadienone raw powder cas 4075-07-4

CAS No.: 4075-07-4

Pharmacy Grade

$14-16/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.